<DOC>
	<DOCNO>NCT00479037</DOCNO>
	<brief_summary>The primary objective trial show PTH ( 1-84 ) superior strontium ranelate bone formation measure change bone formation marker treatment period 24 week postmenopausal woman primary osteoporosis .</brief_summary>
	<brief_title>Effect Full Length Parathyroid Hormone , PTH ( 1-84 ) Strontium Ranelate Bone Markers Postmenopausal Women With Primary Osteoporosis ( FP-006-IM )</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Strontium ranelate</mesh_term>
	<criteria>Postmenopausal woman age 50 , diagnose primary osteoporosis may enrol trial follow inclusion/exclusion criterion apply . All inclusion criterion must answer `` yes '' subject enrol trial . 1 . Has subject give informed consent accord local requirement trial related activity ? ( A trial related activity procedure would perform routine management subject ) . 2 . Is subject female age 50 ? 3 . Has subject postmenopausal 5 year judgement investigator ? 4 . Does subject primary osteoporosis Tscore equal low 2.5 SD ; Tscores must assess DXA lumbar spine L1L4 , minimum two assessable vertebra , total hip ( right hip , right hip prosthesis , leave hip use . If hip replace subject include lumbar scan ) . 5 . Is subject currently take calcium vitamin D3 willing start supplemental treatment continue throughout trial period , unless develops hypercalcaemia ? 6 . Has subject take supplemental calcium ( 1,000 mg ) vitamin D3 ( 800 IU ) daily least 14 day ( screen ) blood sample eligibility evaluation ? [ * ] 7 . Is subject able selfinject PTH ( 184 ) , get injection helper ? [ * ] Note inclusion criterion . 6 evaluated time screening , must evaluate randomisation , visit 2 . See also exclusion criterion note [ ** ] . Exclusion criterion : All exclusion criterion must answer `` '' subject enrol trial . Has subject : 1. treat SERMS ( selective oestrogen receptor modulators ) calcitonin within last 1 month ? 2. ever treat bisphosphonate intravenous form ( i.v. ) ? 3. treated bisphosphonates ( alendronate , risedronate , bisphosphonates ) 3 year total , within last 6 month ? 4. treat fluoride 3 month within last 10 year ? 5. ever treat strontium ranelate ? 6. ever treat teriparatide PTH ( 184 ) ? 7. receive subject currently receive chronic glucocorticosteroid treatment ? Defined equal : 5.0 mg prednisolon equivalent daily 3 month last year 2.5 mg prednisolon equivalent daily 6 month last year . Local inhalation steroid permit . 8. treated cancer ( basocellular skin cancer ) within last 5 year ? 9. ever receive radiation therapy skeleton ? 10. ever malignant disease affect skeleton ? subject : 11. currently receive antiepileptic medication ? 12. take medication ( calcium vitamin D3 ) know affect bone metabolism ? accord investigator 's opinion . 13. know clinically significant disease affect calcium metabolism ? 14. known history metabolic bone diseases primary osteoporosis include hyperparathyroidism , Paget 's disease , osteogenesis imperfecta , osteomalacia ) ? 15. known history hypersensitivity parathyroid hormone strontium excipients product ? 16. serum vitamin D3 , ( serum 25 ( OH ) D ) level &lt; 20 ng/ml least 14 day calcium vitamin D3 supplementation ? [ ** ] 17. serum PTH &gt; 65 pg/ml also total serum calcium value &gt; 2.49 mmol/l ? [ ** ] 18. hypercalcaemia ( total serum calcium value &gt; 2.55 mmol/l ) , measure least 14 day calcium vitamin D3 supplementation ? [ ** ] 19. elevate serum alkaline phosphatase ? Defined &gt; 3X ULN [ ** ] 20. impaired kidney function creatinine clearance &lt; 30 ml/min ( indirect measurement serum creatinine ) ? [ ** ] 21. severe impair liver function ? [ ** ] 22. phenylketonuria ? subject : 23. risk venous thromboembolism include pulmonary embolism ? accord investigator 's opinion . 24. schedule vertebroplasty ? 25. currently participate clinical trial investigational medical product , do within last 90 day , plan within next 32 week ? Previous current participation noninterventional trial allow . [ ** ] exclusion criterion . 16 21 evaluated result blood sampling ( plan within screen period least 14 day supplemental calcium/vitamin D3 intake ) available .</criteria>
	<gender>Female</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>postmenopausal woman primary osteoporosis</keyword>
</DOC>